Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment
Immunology & Cell Biology · 2026-08 · 104 (7) · 711-728
DOI: 10.1111/imcb.70144 ↗At a glance
Übersichtsarbeit in Immunology & Cell Biology, published online on 2026-07-03. Written by Emerson Achari and 6 co-authors. Institution: Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia. Major MEDLINE topics: Glioblastoma, Drug Resistance, Neoplasm, Brain Neoplasms. Cited 2 times so far (Crossref); 195 references. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
High‐grade central nervous system cancers incur a significant burden of care on society. The combination of therapeutic resistance and high mortality makes it both a challenging target and a devastating diagnosis. Of these, one in two is characterized as glioblastoma (GBM) with a median survival rate of only 13.5 months with the current standard of therapy. Modern interventions, such as PD‐1 and CTLA‐4 checkpoint inhibition and autologous CAR T cell delivery, remain stymied by both the difficult nature of drug delivery to the brain and the inherent immunosuppressive tumor microenvironment. However, recent advances in the characterization of GBM have unveiled promising new therapeutic avenues aiming to target and eliminate the tumor. In this review, we summarize the mechanisms through which GBM is initiated, localized, and eludes therapy responses and provide an update on recent advances made within this therapeutic space to overcome GBM‐mediated immunosuppression. We also discuss the challenges with current and next generational treatment strategies before finally exploring the landscape of potential future therapeutic targets.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia.
- Fiona Elsey Cancer Research Institute, Ballarat, Victoria, Australia.
- Federation University Australia, Ballarat, Victoria, Australia.
- Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany.
- Department of Neurosurgery, University Hospital Bonn, Bonn, Germany.
- Department of Surgery, Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia.
ORCID profiles: Amit Sharma
Cite
APA
Achari, E., Ahmady-Nield, F., Sharma, A., Schmidt-Wolf, I. G. H., Maciaczyk, J., Luwor, R. B., & Achuthan, A. A. (2026). Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment. Immunology & Cell Biology, 104(7), 711-728. https://doi.org/10.1111/imcb.70144
Vancouver
Achari E, Ahmady-Nield F, Sharma A, Schmidt-Wolf IGH, Maciaczyk J, Luwor RB, et al. Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment. Immunology & Cell Biology. 2026;104(7):711-728. doi:10.1111/imcb.70144
BibTeX
@article{Achari2026,
author = {Achari, Emerson and Ahmady-Nield, Farah and Sharma, Amit and Schmidt-Wolf, Ingo G H and Maciaczyk, Jarek and Luwor, Rodney B and Achuthan, Adrian A},
title = {Mechanisms of Therapeutic Resistance and Recent Advances in Glioblastoma Treatment},
journal = {Immunology & Cell Biology},
year = {2026},
volume = {104},
number = {7},
pages = {711--728},
doi = {10.1111/imcb.70144}
}
EUVIMED